SIRs for non-germinal center neoplasms in autoimmune disease patients.

<p>SIRs for non-germinal center neoplasms in autoimmune disease patients.</p

SIR for non-germinal center neoplasms in autoimmune disease patients.

<p>Red bars show significant and blue bars not significant associations.</p

SIRs for primarily germinal center-derived neoplasms in autoimmune disease patients.

<p>Red bars show significant and blue bars not significant associations.</p

Odds ratios (ORs) for TNM classes in postmenopausal lobular carcinoma by reproductive factors.

<p>Bold type: 95% CI does not include 1.00. The ORs were adjusted for:</p><p>1. Age at diagnosis, region, and occupation.</p><p>2. Age at diagnosis, region, occupation, and parity.</p>*<p>Carcinoma in situ.</p>**<p>The number of cases for T2 (N = 1,106), T3 (236), and T4 (75).</p

Odds ratios (ORs) for TNM classes in premenopausal ductal carcinoma by reproductive factors.

<p>Bold type: 95% CI does not include 1.00. The ORs were adjusted for:</p><p>1. Age at diagnosis, region, and occupation.</p><p>2. Age at diagnosis, region, occupation, and parity.</p>*<p>Carcinoma in situ.</p>**<p>The number of cases for T2 (N = 1,047), T3 (176), and T4 (65).</p

Odds ratios (ORs) for TNM classes in postmenopausal breast cancer by reproductive factors.

<p>Bold type: 95% CI does not include 1.00. The ORs were adjusted for:</p><p>1. Age at diagnosis, region, and occupation.</p><p>2. Age at diagnosis, region, occupation, and parity.</p>*<p>Carcinoma in situ.</p>**<p>The number of cases for T2 (N = 6,098), T3 (871), and T4 (654).</p

Odds ratios (ORs) for TNM classes in postmenopausal breast cancer by age at first and last childbirth, stratified by time interval between first and last childbirth.

<p>Bold type: 95% CI does not include 1.00.</p><p>Women with two or more children were included. ORs were adjusted for parity, region and occupation.</p>*<p>Carcinoma in situ.</p

SIRs for leukemia in T1DM patients according to age at leukemia diagnosis.

<p>O, observed; SIR, standardized incidence ratio; CI, confidence interval; *P<0.05, **P<0.01.</p><p>Case numbers in the reference population ALL: 1733 (<10 y), 701 (10–20 y), 562 (21–50 y), 2996 (total); CLL: 55 (<10 y), 15 (10–20 y), 728 (21–50 y), 798 (total); AML: 301 (<10 y), 296 (10–20 y), 1506 (21–50 y), 2103 (total); CML: 88 (<10 y), 93 (10–20 y), 1201 (21–50 y), 1382 (total).</p

SIRs for leukemia in T1D patients according to time at hospitalization for T1D and age at T1D diagnosis.

<p>O, observed; SIR, standardized incidence ratio; CI, confidence interval;</p>*<p>P<0.05, **P<0.01.</p

Age-specific incidence of leukemia in T1D patients (symbols in three age bands, 0–9 y, 10–19 y and 20–49 y) compared to the Swedish background rate (solid lines in 10–year age bands).

<p>The case numbers for T1D patients are shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039523#pone-0039523-t001" target="_blank">Table 1</a> and those for the background rates in footnote to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039523#pone-0039523-t001" target="_blank">Table 1</a>.</p